{
    "clinical_study": {
        "@rank": "100692", 
        "arm_group": {
            "arm_group_label": "Treatment (pomalidomide, bortezomib, and dexamethasone)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive pomalidomide PO on days 1-21; bortezomib IV on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and best dose of pomalidomide and bortezomib\n      when given together with dexamethasone in treating patients with amyloid light-chain\n      amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide,\n      may stimulate the immune system in different ways and stop abnormal cells from growing.\n      Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for\n      cell growth. Giving pomalidomide and bortezomib together with dexamethasone may be an\n      effective treatment for amyloid light-chain amyloidosis or light chain deposition disease"
        }, 
        "brief_title": "Pomalidomide, Bortezomib, and Dexamethasone as First-Line Treatment in Treating Patients With Amyloid Light-Chain Amyloidosis or Light Chain Deposition Disease", 
        "condition": [
            "Light Chain Deposition Disease", 
            "Primary Systemic Amyloidosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Amyloidosis", 
                "Multiple Myeloma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Establish the maximum tolerated dose (MTD) of the combination of pomalidomide,\n      bortezomib, and dexamethasone (PVD) to take forward in a subsequent phase 2 study.\n\n      SECONDARY OBJECTIVES:\n\n      I. Obtain a preliminary assessment of efficacy of PVD regimen as initial treatment of\n      amyloid light-chain (AL) or light chain deposition disease (LCDD).\n\n      OUTLINE: This is a dose-escalation study of pomalidomide and bortezomib.\n\n      Patients receive pomalidomide orally (PO) on days 1-21; bortezomib intravenously (IV) on\n      days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28\n      days in the absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up at least every 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Understand and voluntarily sign an informed consent form\n\n          -  Able to adhere to the study visit schedule and other protocol requirements\n\n          -  Histologically confirmed AL or LCDD (from any time prior to screening)\n\n          -  Up to one cycle of prior therapy is allowed (maximum of 120 mg total dexamethasone\n             (or equivalent amount of prednisone), 4 days of melphalan, and/or 4 doses of velcade;\n             at least 4 weeks has to have had passed since last dose of melphalan, 2 weeks since\n             last velcade or glucocorticoid dose\n\n          -  Measurable disease, as defined by:\n\n               -  Serum monoclonal protein >= 0.5 g/dL by serum electrophoresis\n\n               -  Urine monoclonal protein > 200 mg/tv in a 24 hour urine electrophoresis\n\n               -  A difference between the involved immunoglobulin free light chain and uninvolved\n                  light chain of >= 5 mg/dL AND abnormal serum immunoglobulin kappa lambda free\n                  light chain ratio\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 at study entry\n\n          -  Demonstrated clonal population of plasma cells in the bone marrow or positive\n             immunohistochemical stain with anti-light chain anti-sera of amyloid fibrils\n\n          -  Absolute neutrophil count >= 1000/mm^3\n\n          -  Platelet count >= 75,000/mm^3\n\n          -  Serum creatinine =< 2.5 mg/dL\n\n          -  Total bilirubin =< 1.5 mg/dL\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and\n             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x\n             upper limit of normal (ULN)\n\n          -  Disease free of prior malignancies for >= 5 years with exception of currently treated\n             basal cell, squamous cell carcinoma of the skin, or carcinoma \"in situ\" of the cervix\n             or breast\n\n          -  Females of childbearing potential (FCBP) must have a negative serum or urine\n             pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to\n             and again within 24 hours of starting pomalidomide and must either commit to\n             continued abstinence from heterosexual intercourse or begin TWO acceptable methods of\n             birth control, one highly effective method and one additional effective method AT THE\n             SAME TIME, at least 28 days before she starts taking pomalidomide; FCBP must also\n             agree to ongoing pregnancy testing; men must agree to use a latex condom during\n             sexual contact with a FCBP even if they have had a vasectomy; all patients must be\n             counseled at a minimum of every 28 days about pregnancy precautions and risks of\n             fetal exposure\n\n          -  Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients\n             intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight\n             heparin), unless baseline prothrombin time [PT] or partial thromboplastin time [PTT]\n             is >= 1.5 ULN, in which case thromboprophylaxis is not required\n\n        Exclusion Criteria:\n\n          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that\n             would prevent the subject from signing the informed consent form\n\n          -  Pregnant or breast feeding females; (lactating females must agree not to breast feed\n             while taking pomalidomide)\n\n          -  Any condition, including the presence of laboratory abnormalities, which places the\n             subject at unacceptable risk if he/she were to participate in the study or confounds\n             the ability to interpret data from the study\n\n          -  Use of any other experimental drug or therapy within 28 days of baseline\n\n          -  Known hypersensitivity reaction or history of desquamating rash related to\n             thalidomide or lenalidomide\n\n          -  Known hypersensitivity to bortezomib, boron, or any of the other agents utilized in\n             this protocol\n\n          -  Patient has >= grade 3 peripheral sensory neuropathy or >= grade 2 painful sensory\n             neuropathy within 14 days before enrollment; (NOTE: patient with peripheral\n             neuropathy [PN] that was previously this severe but is currently improved due to\n             ongoing therapy [e.g., gabapentin or amitriptyline] may be eligible)\n\n          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart\n             Association (NYHA) class III or IV heart failure, uncontrolled angina, severe\n             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute\n             ischemia or active conduction system abnormalities (not including 1st degree\n             atrioventricular (AV)-block, Wenckebach type 2nd degree heart block, or left bundle\n             branch block; prior to study entry, any electrocardiogram (ECG) abnormality at\n             screening has to be documented by the investigator as not medically relevant); note:\n             there is no lower limit of left ventricular ejection fraction below which patients\n             are excluded from participation\n\n          -  Concurrent use of other anti-cancer agents or treatments\n\n          -  Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type\n             A, B or C\n\n          -  Meets criteria for symptomatic multiple myeloma, defined as:\n\n               -  >= 30% monoclonal plasma cells in the marrow AND ANY OF THE FOLLOWING:\n\n                    -  Biopsy-confirmed plasmacytoma\n\n                    -  Lytic bone lesion(s)\n\n                    -  Hypercalcemia without other explanation\n\n               -  NOTE: patients with >= 30% marrow plasma cells WITHOUT any other criteria to\n                  suggest myeloma except for symptoms related to amyloidosis ARE potentially\n                  eligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728259", 
            "org_study_id": "2011-155", 
            "secondary_id": "NCI-2012-02228"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (pomalidomide, bortezomib, and dexamethasone)", 
                "description": "Given PO", 
                "intervention_name": "pomalidomide", 
                "intervention_type": "Drug", 
                "other_name": "CC-4047"
            }, 
            {
                "arm_group_label": "Treatment (pomalidomide, bortezomib, and dexamethasone)", 
                "description": "Given IV", 
                "intervention_name": "bortezomib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "LDP 341", 
                    "MLN341", 
                    "VELCADE"
                ]
            }, 
            {
                "arm_group_label": "Treatment (pomalidomide, bortezomib, and dexamethasone)", 
                "description": "Given PO", 
                "intervention_name": "dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aeroseb-Dex", 
                    "Decaderm", 
                    "Decadron", 
                    "DM", 
                    "DXM"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Bortezomib", 
                "Thalidomide", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Jeffrey.Matous@HealthONEcares.com", 
                    "last_name": "Jeffrey V. Matous", 
                    "phone": "720-754-4800"
                }, 
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Colorado Blood Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Jeffrey V. Matous", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "vaishali.sanchorawala@bmc.org", 
                    "last_name": "Vaishali Sanchorawala", 
                    "phone": "617-638-7523"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118-2393"
                    }, 
                    "name": "Boston University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Vaishali Sanchorawala", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "zonderj@karmanos.org", 
                    "last_name": "Jeffrey A. Zonder", 
                    "phone": "313-576-9363"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Barbara Ann Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Jeffrey A. Zonder", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gaspa001@mc.duke.edu", 
                    "last_name": "Cristina Gasparetto", 
                    "phone": "919-668-1017"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Cristina Gasparetto", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Donna.Reece@uhn.ca", 
                    "last_name": "Donna E. Reece", 
                    "phone": "2M916-946-2000"
                }, 
                "facility": {
                    "address": {
                        "city": "Cashmere", 
                        "country": "New Zealand", 
                        "state": "Canterbury", 
                        "zip": "8022"
                    }, 
                    "name": "Princess Margaret Hospital"
                }, 
                "investigator": {
                    "last_name": "Donna E. Reece", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease", 
        "overall_official": {
            "affiliation": "Barbara Ann Karmanos Cancer Institute", 
            "last_name": "Jeffrey Zonder", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum tolerated dose defined as the dose level before 2 of 6 patients experience dose-limiting toxicity (DLT) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728259"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Barbara Ann Karmanos Cancer Institute", 
            "investigator_full_name": "Jeffrey Zonder", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Will be estimated and reported with 95% confidence intervals.", 
                "measure": "Complete hematologic response rate (hCR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "measure": "Overall hematologic response rate (partial response [PR] + complete response [CR])", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "description": "Organ responses will be tabulated and reported for all patients with cardiac, renal, hepatic, and/or neurologic involvement by amyloidosis.", 
                "measure": "Organ response rates (heart, liver, kidney)", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "description": "Will be estimated and reported with 95% confidence interval.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From date of registration to date of death, assessed up to 28 days"
            }, 
            {
                "description": "Will be estimated and reported with 95% confidence interval.", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }
        ], 
        "source": "Barbara Ann Karmanos Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Barbara Ann Karmanos Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}